Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

doi:10.1007/s00259-024-06680-3

Editorial

. 2024 May;51(6):1574-1577.

doi: 10.1007/s00259-024-06680-3.

Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

Wenpeng Huang¹, Mai Hong Son², Le Ngoc Ha², Lei Kang³, Weibo Cai⁴

Affiliations

¹ Department of Nuclear Medicine, Peking University First Hospital, No.8 Xishiku Str, Xicheng District, Beijing, 100034, China.
² Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
³ Department of Nuclear Medicine, Peking University First Hospital, No.8 Xishiku Str, Xicheng District, Beijing, 100034, China. kanglei@bjmu.edu.cn.
⁴ Departments of Radiology and Medical Physics, University of Wisconsin - Madison, K6/562 Clinical Science Center, 600 Highland Ave, Madison, WI, 53705-2275, USA. wcai@uwhealth.org.

PMID: 38492018
PMCID: PMC11131584 (available on 2025-05-01)
DOI: 10.1007/s00259-024-06680-3

Editorial

Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

Wenpeng Huang et al. Eur J Nucl Med Mol Imaging. 2024 May.

. 2024 May;51(6):1574-1577.

doi: 10.1007/s00259-024-06680-3.

Authors

Wenpeng Huang¹, Mai Hong Son², Le Ngoc Ha², Lei Kang³, Weibo Cai⁴

Affiliations

¹ Department of Nuclear Medicine, Peking University First Hospital, No.8 Xishiku Str, Xicheng District, Beijing, 100034, China.
² Department of Nuclear Medicine, Hospital 108, Hanoi, Vietnam.
³ Department of Nuclear Medicine, Peking University First Hospital, No.8 Xishiku Str, Xicheng District, Beijing, 100034, China. kanglei@bjmu.edu.cn.
⁴ Departments of Radiology and Medical Physics, University of Wisconsin - Madison, K6/562 Clinical Science Center, 600 Highland Ave, Madison, WI, 53705-2275, USA. wcai@uwhealth.org.

PMID: 38492018
PMCID: PMC11131584 (available on 2025-05-01)
DOI: 10.1007/s00259-024-06680-3

No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest Weibo Cai declares conflict of interest with the following corporations: Actithera, Inc., Rad Source Technologies, Inc., Portrai, Inc., rTR Technovation Corporation, and Four Health Global Pharmaceuticals, Inc. All other authors declare no conflict of interest.

References

1. Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, et al. 18F FDG PET/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022;304:246–64. - PubMed
1. Li X, Younis MH, Wei W, Cai W. PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: illuminating the path of image-guided cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2023;50:2240–3. - PMC - PubMed
1. Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, et al. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022;10:e004026. - PMC - PubMed
1. Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of High tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8:1160–8. - PMC - PubMed
1. Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234:1313–25. - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

Grants and funding

P30 CA014520/CA/NCI NIH HHS/United States

LinkOut - more resources

Full Text Sources
- Springer
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, et al. 18F FDG PET/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022;304:246–64. - PubMed

[2] Hughes DJ, Subesinghe M, Taylor B, Bille A, Spicer J, Papa S, et al. 18F FDG PET/CT and novel molecular imaging for directing immunotherapy in cancer. Radiology. 2022;304:246–64. - PubMed

[3] Li X, Younis MH, Wei W, Cai W. PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: illuminating the path of image-guided cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2023;50:2240–3. - PMC - PubMed

[4] Li X, Younis MH, Wei W, Cai W. PD-L1 - targeted magnetic fluorescent hybrid nanoparticles: illuminating the path of image-guided cancer immunotherapy. Eur J Nucl Med Mol Imaging. 2023;50:2240–3. - PMC - PubMed

[5] Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, et al. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022;10:e004026. - PMC - PubMed

[6] Chen X, Wang K, Jiang S, Sun H, Che X, Zhang M, et al. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma. J Immunother Cancer. 2022;10:e004026. - PMC - PubMed

[7] Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of High tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8:1160–8. - PMC - PubMed

[8] Ricciuti B, Wang X, Alessi JV, Rizvi H, Mahadevan NR, Li YY, et al. Association of High tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels. JAMA Oncol. 2022;8:1160–8. - PMC - PubMed

[9] Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234:1313–25. - PubMed

[10] Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol. 2019;234:1313–25. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

Affiliations

Challenges coexist with opportunities: development of a macrocyclic peptide PET radioligand for PD-L1

Authors

Affiliations

Conflict of interest statement

Similar articles

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Research Materials